HPHA

EQS-News: Heidelberg Pharma Announces Royalty Financing Agreement with HealthCare Royalty for up to USD 115 million

Retrieved on: 
Wednesday, March 13, 2024

Ladenburg, Germany, 4 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed a royalty financing agreement.

Key Points: 
  • Ladenburg, Germany, 4 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech Company developing innovative Antibody Drug Conjugates (ADCs), and HealthCare Royalty (HCRx) today announced that they have signed a royalty financing agreement.
  • Key terms of the agreement between Heidelberg Pharma and HCRx:
    Following the receipt by HCRx of a maximum cumulative amount, royalty payments will revert to Heidelberg Pharma and HCRx will receive a low single digit royalty tail percentage thereafter
    Prof. Dr. Andreas Pahl, Chief Executive Officer at Heidelberg Pharma, commented: “We are delighted to partner with HealthCare Royalty.
  • This agreement will provide us with a non-dilutive financing based on expected royalty payments from the worldwide sales of ZircaixTM.
  • Heidelberg Pharma will hold a conference call on 25 March 2024 with the publication of the Annual Report.

EQS-News: Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024

Retrieved on: 
Wednesday, March 13, 2024

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Ladenburg, Germany, 6 March 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs) will be presenting first efficacy data on its Phase I clinical trial with ATAC candidate HDP-101 as well as preclinical data on other drug candidates from its proprietary ADC technology platform at the American Association for Cancer Research (AACR) Annual Meeting, being held in San Diego, California on the 5 - 10 April 2024.
  • Details of the conference and poster presentations are as follow:

Korean Semiconductor Equipment Provider HPSP expands its R&D capabilities and study on High-Pressure Annealing and Oxidation

Retrieved on: 
Wednesday, January 17, 2024

SEOUL, South Korea, Jan. 17, 2024 /PRNewswire/ -- HPSP, a South Korean semiconductor equipment provider, is strengthening its research and development (R&D) programs regarding High-Pressure Annealing (HPA) and High Pressure Oxidation (HPO). With the upcoming grand opening of its new R&D center in Korea, HPSP has established new programs and tools with advanced capabilities to extend existing HPA and HPO technology beyond traditional process regimes. The addition of HPO and New HPA with the various gases builds on High Pressure Hydrogen Annealing (HPHA) which has become an essential step especially in advanced node.

Key Points: 
  • SEOUL, South Korea, Jan. 17, 2024 /PRNewswire/ -- HPSP, a South Korean semiconductor equipment provider, is strengthening its research and development (R&D) programs regarding High-Pressure Annealing (HPA) and High Pressure Oxidation (HPO).
  • High Pressure Hydrogen Annealing (HPHA) is a process for improving the reliability and performance of semiconductor devices by curing defects in semiconductor devices, applicable in various fields.
  • Given that the scale down of semiconductor manufacturing is becoming more and more intensive and the thermal budget is becoming tighter, the use of conventional annealing equipment or high temperature annealing equipment in semiconductor annealing process is becoming more and more difficult.
  • HPSP believes that this will pave the way for chip makers to enhance the performance and reliability of their semiconductor devices and bring cutting-edge products to the market.

EQS-News: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform

Retrieved on: 
Thursday, December 14, 2023

Ladenburg, Germany, 15 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH has been granted a patent covering site-specific ATAC conjugates by the European Patent Office (EPO).

Key Points: 
  • Ladenburg, Germany, 15 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that its subsidiary Heidelberg Pharma Research GmbH has been granted a patent covering site-specific ATAC conjugates by the European Patent Office (EPO).
  • Site-specific ATAC conjugates comprise a genetically engineered antibody to which Heidelberg Pharma’s proprietary amatoxin payloads can be coupled via specific linkers.
  • The European patent also covers a method for the synthesis of such conjugates as well as their use in the treatment of diseases.
  • Professor Andreas Pahl, Chief Scientific Officer of Heidelberg Pharma, comments: "We are very pleased that this patent has been granted, as it protects essential aspects of our ATAC technology, as e.g.

EQS-News: Heidelberg Pharma AG: Heidelberg Pharma Announces Changes to the Executive Management Board

Retrieved on: 
Wednesday, December 13, 2023

His successor will be Prof. Dr. Andreas Pahl, Chief Scientific Officer

Key Points: 
  • His successor will be Prof. Dr. Andreas Pahl, Chief Scientific Officer
    Ladenburg, Germany, 29 November 2023 – Heidelberg Pharma AG (FSE: HPHA) today announced that Dr. Jan Schmidt-Brand, Chief Executive Officer (CEO) of Heidelberg Pharma AG and Managing Director of the subsidiary Heidelberg Pharma Research GmbH, is planning to retire at the beginning of February 2024 and step down from his positions.
  • Prof. Pahl has been Head of Research & Development at Heidelberg Pharma since 2012 and has been a member of the Executive Board since 2016.
  • Dr. Schmidt-Brand has been with Heidelberg Pharma since 2001, first as Managing Director of the subsidiary Heidelberg Pharma Research GmbH and since 2012 as a member of the Management Board of Heidelberg Pharma AG.
  • Prof. Christof Hettich, Chairman of the Supervisory Board of Heidelberg Pharma AG, commented: "On behalf of the Supervisory Board, I would like to sincerely thank Dr. Schmidt-Brand for his many years of service on the Executive Management Board of Heidelberg Pharma AG.

EQS-News: Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023

Retrieved on: 
Tuesday, November 7, 2023

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Ladenburg, Germany, 2 November 2023 – Heidelberg Pharma AG (FSE: HPHA) will present new findings of its clinical Phase I/IIa study with the proprietary ADC candidate HDP-101 at the 65th Annual Meeting of the American Society of Hematology (ASH).
  • Dr. András Strassz, Chief Medical Officer at Heidelberg Pharma, commented: “We are very pleased with the progress of patient enrollment in our clinical trial with HDP-101.
  • So far, HDP-101 has shown to be safe and well tolerated, and we will continue dose escalation in the fifth patient cohort (100 µg/kg) as planned.”

EQS-News: Heidelberg Pharma AG: Heidelberg Pharma Provides Update on Phase I/IIa Clinical Trial with Lead Candidate HDP-101

Retrieved on: 
Monday, September 25, 2023

Ladenburg, Germany, 19 September 2023 – Heidelberg Pharma AG (FSE: HPHA) announced today that the clinical Phase I/IIa study with the lead development candidate HDP-101 has already started to recruit patients for the fifth patient cohort with a dosing of 100 µg/kg.

Key Points: 
  • Ladenburg, Germany, 19 September 2023 – Heidelberg Pharma AG (FSE: HPHA) announced today that the clinical Phase I/IIa study with the lead development candidate HDP-101 has already started to recruit patients for the fifth patient cohort with a dosing of 100 µg/kg.
  • The Safety Review Committee's (SRC) evaluation of patient data concluded that no dose-limiting toxicities have occurred to date.
  • The first four dose levels have shown to be safe and well tolerated.
  • One patient from the third cohort has now been on HDP-101 monotherapy for over nine months and has been treated with eleven doses.

EQS-News: Heidelberg Pharma AG: Heidelberg Pharma’s Partner Takeda Reached Development Milestone

Retrieved on: 
Tuesday, August 8, 2023

Ladenburg, Germany, 8 August 2023 – Heidelberg Pharma AG (FSE: HPHA) announced today that its partner Takeda reached a development milestone for starting a GLP (Good Laboratory Practice) toxicology study for an Antibody Targeted Amanitin Conjugate.

Key Points: 
  • Ladenburg, Germany, 8 August 2023 – Heidelberg Pharma AG (FSE: HPHA) announced today that its partner Takeda reached a development milestone for starting a GLP (Good Laboratory Practice) toxicology study for an Antibody Targeted Amanitin Conjugate.
  • Upon achievement of the milestone, Heidelberg Pharma received a milestone payment.
  • Prof. Andreas Pahl, CSO of Heidelberg Pharma AG, commented: "We are happy that the development of Takeda’s ATAC candidate, an Amanitin-based ADC, is progressing successfully and that the important GLP study was started.
  • In 2022, Takeda exclusively licensed the worldwide development and commercialization rights from Heidelberg Pharma for the use of the ATAC technology with an antibody directed to a defined target and the resulting product candidates.

EQS-News: Heidelberg Pharma Reports on First Half-Year 2023 and the Course of Business

Retrieved on: 
Thursday, July 13, 2023

Ladenburg, Germany, 13 July 2023 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2023 (1 December 2022 - 31 May 2023).

Key Points: 
  • Ladenburg, Germany, 13 July 2023 - Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2023 (1 December 2022 - 31 May 2023).
  • HDP-101 (BCMA-ATAC) program: Heidelberg Pharma presented preliminary safety data from the clinical trial with HDP-101.
  • The Heidelberg Pharma Group (Heidelberg Pharma) – comprising Heidelberg Pharma AG and its subsidiary Heidelberg Pharma Research GmbH – reports consolidated figures.
  • The full-year financial guidance issued on 24 March 2023 for the Heidelberg Pharma Group is confirmed at this time.

EQS-News: Heidelberg Pharma reports on the results of the Annual General Meeting 2023

Retrieved on: 
Saturday, May 27, 2023

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Ladenburg, Germany, 25 May 2023 - Heidelberg Pharma AG (FSE: HPHA) announced that the company's shareholders approved the following proposed resolutions of the management with a large majority (between 96,30 % and 99,99 %) at today's ordinary virtual Annual General Meeting:
    Amendments to the Articles of Association relating to the holding of a virtual Annual General Meeting, the virtual participation of Supervisory Board members and the quorum of the Supervisory Board
    Authorization to grant subscription rights (Heidelberg Pharma Stock Option Plan 2023), reduction of individual Conditional Capitals, creation of a Conditional Capital 2023/I, and corresponding amendments to the Articles of Association
    Attendance (incl.
  • postal votes cast) at the Annual General Meeting 2023 corresponded to 84,24 % of the current capital stock.
  • For more information on the Annual General Meeting, including the voting results, please visit: https://heidelberg-pharma.com/en/agm